发明名称 |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
摘要 |
The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) complex. Preferably, the DNL™ complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-α2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6. The anti-IGF-1R antibody or complex may be administered alone or in combination with a therapeutic agent, such as an mTOR inhibitor. |
申请公布号 |
US8883162(B2) |
申请公布日期 |
2014.11.11 |
申请号 |
US201213688812 |
申请日期 |
2012.11.29 |
申请人 |
IBC Pharmaceuticals, Inc. |
发明人 |
Chang Chien-Hsing;Goldenberg David M. |
分类号 |
A61K39/395;A61K39/44;C07K16/30;A61P35/02;A61P35/00;A61K51/08;B82Y5/00;C07K16/46;A61K47/48;C07K16/28;B82Y10/00 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
Nakashima Richard A. |
主权项 |
1. A method of treating a cancer that expresses IGF-1R comprising:
a) administering a complex to an individual with the cancer, wherein the complex comprises:
(i) an anti-IGF-1R IgG antibody or antigen-binding fragment thereof attached to one or more anchor domain (AD) moieties from an AKAP protein; and(ii) two or more copies of an effector attached to a dimerization and docking domain (DDD) moiety from a human protein kinase A (PKA) regulatory subunit RIα, RIβ, RIIα or RIIβ, wherein the effector is a second antigen-binding antibody fragment or a cytokine; and b) administering a therapeutic agent to the individual;wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the complex. |
地址 |
Morris Plains NJ US |